Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02161016 · ClinicalTrials.gov registry record · Phase 4
A Clinical Study of Outcomes in Foot and Ankle Bone Grafting Using map3® Cellular Allogeneic Bone Graft
A Phase 4 study, sponsored by RTI Surgical.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT02161016 is a Phase 4 study that was terminated before completion, run by RTI Surgical. The registered enrollment target is 1 participants.
The verdict
NCT02161016, a Phase 4 study, was terminated before completion, sponsored by RTI Surgical.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a single arm pilot study in patients requiring surgical fusion in the foot or ankle. Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells. This cohort study will enroll 24 patients total at 1 site. After subjects have signed an informed consent, the baseline visit and examinations will be completed. Patients will be evaluated at 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 24 months after surgery.
Interventions
- DEVICE map3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02161016
The ClinicalTrials.gov registry entry for NCT02161016 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RTI Surgical, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which map3 is the first listed.
NCT02161016 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02161016 about?
NCT02161016 is a clinical study titled "A Clinical Study of Outcomes in Foot and Ankle Bone Grafting Using map3® Cellular Allogeneic Bone Graft". This is a single arm pilot study in patients requiring surgical fusion in the foot or ankle. Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells. This cohort study will enroll 24 patients total at 1 site. After subjects have signed an informed consent, the ...
What is the current status of trial NCT02161016?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2014-06. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02161016?
The interventions under investigation include: map3 (DEVICE).
Who is sponsoring clinical trial NCT02161016?
This trial is sponsored by RTI Surgical, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.